Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of almost 20 different brokers. See the list of analysts and their contact details here

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" as subject.  

 ucb

UCB FY Consensus Product Sales Estimates (Average)

In € million 2017a 2018e 2019e 2020e  2021e  2022e  2023e
Cimzia 1,424 1,456 1,513 1,516 1,509 1,477 1,424
Vimpat 976 1,088 1,218 1,328 1,436 1,148 821
Neupro 314 320 334 347 309 252 217
Briviact 87 143 214 282 347 406 465
Keppra 778 746 716 687 632 587 547

 

UCB FY Consensus Earnings Estimates (Average)

In € million 2017a 2018e 2019e 2020e 
Net Sales  4,182 4,339  4,549  4,721 
Revenue  4,530 4,600 4,791 4,957
Recurring EBIT 1,130  1,113 1,145 1,230
Recurring EBITDA 1,375  1,353 1,382 1,470
Net Profit   753 808 828 904
Core EPS (€) 4.82  4.67 4.82 5.22

 

UCB FY Consensus Product Sales Estimates (Median)

In € million 2017a 2018e 2019e 2020e  2021e  2022e  2023e
Cimzia 1,424 1,452 1,506 1,523 1,504 1,460 1,393
Vimpat 976 1,090 1,206 1,319 1,387 1,132 818
Neupro 314 316 327 340 306 236 195
Briviact 87 143 216 287 349 412 466
Keppra 778 778 734 708 647 592 551

 

UCB FY Consensus Earnings Estimates (Median)

In € million 2017a 2018e 2019e 2020e 
Net Sales  4,182 4,333 4,533  4,697 
Revenue  4,530 4,599 4,763 4,928
Recurring EBIT 1,130  1,106 1,134 1,206
Recurring EBITDA  1,375 1,352 1,379 1,461
Net Profit  753  792 805 880
Core EPS (€)  4.82 4.68 4.80 5.13

Downloads:
UCB FY 2018 Consensus (Excel)
UCB FY P&L Consensus (PDF)
UCB FY Product Sales Consensus (PDF)

Last updated: 13 February, 2019



Check out UCB's new IR Apps: 

App Apple Store

App Google Play

 

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.